INDIANA FAMILY AND SOCIAL SERV: $91.9M Department of Health and Human Services Grant

This contract is a federal grant from the Substance Abuse and Mental Health Services Administration (SAMHSA) to the state of Indiana, specifically its Family and Social Services Administration. The $91.9 million award supports Indiana's statewide opioid and stimulant response, covering evidence-based practices, workforce expansion, and overdose prevention. The recipient is a state government agency, not a publicly traded corporation. Therefore, no direct stock impact flows to a public company.

The contract is part of the U.S. Department of Health and Human Services' ongoing State Opioid Response (SOR) grant program, which began in 2018. Indiana's SOR 4 grant continues efforts to address addiction, reduce overdose deaths, and expand access to treatment and recovery resources. While no public company directly receives this funding, the broader healthcare sector—particularly companies involved in addiction treatment services, naloxone manufacturing (e.g., Emergent BioSolutions, which makes Narcan), and behavioral health technologies—may experience indirect tailwinds from sustained federal investment in substance use disorder programs. However, attributing specific revenue impact to any one firm would be speculative.

The legislation authorizing SAMHSA's opioid response grants is typically tied to appropriations bills and past comprehensive addiction legislation (e.g., the SUPPORT for Patients and Communities Act). No specific related bill signals from the provided list directly match this contract. The grant's multi-year period (2024-2027) provides stable funding for Indiana's initiatives.

From a historical pattern perspective, federal opioid response grants have consistently been awarded to states since 2018, with billions allocated annually. Such grants tend to support a network of contracted local providers, nonprofits, and occasionally for-profit treatment centers. Publicly traded companies with exposure to addiction treatment (e.g., Acadia Healthcare, Universal Health Services) may see indirect volume increases, but this is a small fraction of their overall revenue given the state-level disbursement.